You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A phase 2 trial of R1507, a monoclonal antibody to the insulin‐like growth factor‐1 receptor (IGF‐1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study
|
|---|---|
| Published in |
Cancer (0008543X), May 2014
|
| DOI | 10.1002/cncr.28728 |
| Pubmed ID | |
| Authors |
Alberto S. Pappo, Gilles Vassal, John J. Crowley, Vanessa Bolejack, Pancras C. W. Hogendoorn, Rashmi Chugh, Marc Ladanyi, Joseph F. Grippo, Georgina Dall, Arthur P. Staddon, Sant P. Chawla, Robert G. Maki, Dejka M. Araujo, Birgit Geoerger, Kristen Ganjoo, Neyssa Marina, Jean‐Yves Blay, Scott M. Schuetze, Warren A. Chow, Lee J. Helman |
| Abstract |
Insulin-like growth factor-1 receptor (IGF-1R) is implicated in the pathogenesis of rhabdomyosarcoma (RMS), osteosarcoma (OS), and synovial sarcoma (SS). The authors conducted a multi-institutional phase 2 trial of the monoclonal antibody R1507 in patients with various subtypes of recurrent or refractory sarcomas. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 99 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 1% |
| Netherlands | 1 | 1% |
| Italy | 1 | 1% |
| United Kingdom | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 94 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 19 | 19% |
| Researcher | 17 | 17% |
| Student > Bachelor | 12 | 12% |
| Student > Master | 9 | 9% |
| Other | 8 | 8% |
| Other | 19 | 19% |
| Unknown | 15 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 35 | 35% |
| Biochemistry, Genetics and Molecular Biology | 19 | 19% |
| Agricultural and Biological Sciences | 12 | 12% |
| Nursing and Health Professions | 5 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Other | 7 | 7% |
| Unknown | 18 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 July 2014.
All research outputs
#14,797,724
of 25,394,764 outputs
Outputs from Cancer (0008543X)
#11,265
of 14,100 outputs
Outputs of similar age
#119,912
of 242,288 outputs
Outputs of similar age from Cancer (0008543X)
#88
of 143 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 14,100 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 242,288 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 143 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.